Royal Bank of Canada reaffirmed rating, Citigroup began coverage, and Morgan Stanley boosted price target on Arrowhead Pharmaceuticals.
1 report, 1 independent
Updated Sep 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royal Bank of Canada reaffirmed rating, Citigroup began coverage, and Morgan Stanley boosted price target on Arrowhead Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
-
Royal Bank of Canada
financial institution in Canada
-
Citigroup
American investment bank and financial services corporation
-
Morgan Stanley
U.S. investment bank
- An offering was filed with the SEC on July 22, 2025, involving Simmons Bank, with joint book-running management from Stephens Inc., Keefe, Bruyette & Woods, and Morgan Stanley, and co-management from Robert W. Baird & Co.
- Tesla is advancing its Cybercab deployment in Texas, with 45 vehicles already operational and an event scheduled in Austin.
Related events
- Royal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.
- HSBC issued a buy rating and Royal Bank of Canada dropped Citigroup's target price on October 14, 2026.
- Citigroup raised its target price and Royal Bank of Canada boosted its price objective for Carrier Global Corporation on August 26, 2026.
- Citigroup upped its price objective and gave a 'buy' rating, while Royal Bank of Canada reissued an 'outperform' rating for Abbott Laboratories.
- Citigroup and Royal Bank of Canada issued rating and price objective updates on shares of Brunello Cucinelli.